デフォルト表紙
市場調査レポート
商品コード
1611255

ドライアイ症候群治療市場規模、シェア、動向分析レポート:タイプ別、薬剤別、製品別、剤形別、販売チャネル別、流通チャネル別、地域別、セグメント予測、2025年~2030年

Dry Eye Syndrome Treatment Market Size, Share & Trends Analysis Report By Type, By Drug, By Product, By Dosage Form, By Sales Channel, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030


出版日
ページ情報
英文 120 Pages
納期
2~10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ドライアイ症候群治療市場規模、シェア、動向分析レポート:タイプ別、薬剤別、製品別、剤形別、販売チャネル別、流通チャネル別、地域別、セグメント予測、2025年~2030年
出版日: 2024年11月22日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ドライアイ症候群治療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のドライアイ症候群治療市場規模は、2025~2030年にかけてCAGR 6.5%で拡大し、2030年には92億米ドルに達すると推定されています。

市場の成長は、スクリーンの使用の増加、高齢者の増加、眼疾患の有病率の上昇などの要因に起因しています。

スクリーン付きデバイスの使用の増加、コンピュータの使用の急増、まばたきの回数の減少などが、蒸発性ドライアイ症候群の世界の成長をもたらしています。例えば、2021年のFrontiers Journalによると、パンデミック前と比較した場合、COVID-19パンデミックの間、スクリーンの使用は成人で60~80%増加しました。スクリーンにさらされるとまばたきの回数が66%減少するため、涙の蒸発が促進され、ドライアイにつながります。

処方の受容率が極めて低いため、市場では市販(OTC)が主流となっています。例えば、ドライアイと診断された患者のうち、配合箋による治療を受けているのは10%に過ぎず、75%の患者は配合箋による治療を試したことがないです。しかし、ドライアイ症候群と診断された患者数は、眼科医による診察全体の5~35%を占めています。

さらに、ザイドラやレスタシスのような既存製品は、効果が現れるまでに数ヶ月から数週間かかります。さらに、眼科医によると、これらの製品には忍容性の問題があり、50%もの失敗率があるといいます。このため、市場にはアンメットニーズが存在し、今後数年間に発売されるパイプライン製品に有利な機会が生まれると予想されています。さらに、医薬品に関連する規制が市場全体の成長を妨げています。例えば、2020年、Novartisは、規制当局がキシドラの使用に大きな異議を唱えたため、欧州でのキシドラの使用を自主的に撤回せざるを得なくなりました。

主要企業によるイノベーションと戦略的取り組みが市場を牽引しています。新製品の上市は、各社が採用している一般的な戦略です。例えば、2021年10月、Oyster Point PharmaのTyrvaya(バレニクリン溶液)点鼻スプレーが代替治療アプローチとしてFDAに承認されました。

ドライアイ症候群治療市場レポートハイライト

  • タイプ別では、蒸発性ドライアイ症候群が2024年に最大の市場シェアを占め、予測期間中に最も速いCAGRで成長すると予測されます。
  • 剤形別では、点眼薬/液剤が2024年に64.68%の最大シェアで市場を席巻しました。
  • 薬剤別では、2024年にXiidraセグメントが8.52%の収益シェアで市場全体を支配しました。
  • 流通チャネル別では、利便性の高さからオンライン薬局に対する消費者の嗜好が高まっていることから、オンライン薬局が予測期間中に最も速い速度で成長すると予想されます。
  • 北米は、疾患の高い有病率、認知度の急上昇、治療率の向上により、2023年の市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ドライアイ症候群治療市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ドライアイ症候群治療市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析

第4章 ドライアイ症候群治療市場:タイプ別、推定・動向分析

  • セグメントダッシュボード
  • ドライアイ症候群治療市場:タイプ変動分析
  • ドライアイ症候群治療市場:タイプ別展望
  • 2018~2030年の市場規模と予測と動向分析
  • 蒸発性ドライアイ症候群
  • 涙液減少性ドライアイ症候群

第5章 ドライアイ症候群治療市場:薬剤別、推定・動向分析

  • セグメントダッシュボード
  • ドライアイ症候群治療市場:薬剤変動分析
  • ドライアイ症候群治療市場:薬剤別展望
  • 2018~2030年の市場規模と予測と動向分析
  • シイドラ
  • レスタシス
  • セクア
  • ティルヴァヤ
  • エイスヴィス
  • その他

第6章 ドライアイ症候群治療市場:製品別、推定・動向分析

  • セグメントダッシュボード
  • ドライアイ症候群治療市場:製品変動分析
  • ドライアイ症候群治療市場:製品別展望
  • 2018~2030年の市場規模と予測と動向分析
  • 人工涙液
  • シクロスポリン
  • 局所コルチコステロイド
  • 涙点プラグ
  • 経口オメガサプリメント
  • その他

第7章 ドライアイ症候群治療市場:剤形別、推定・動向分析

  • セグメントダッシュボード
  • ドライアイ症候群治療市場:剤形変動分析
  • ドライアイ症候群治療市場:剤形別展望
  • 2018~2030年の市場規模と予測と動向分析
  • 点眼薬/溶液
  • 軟膏とジェル
  • カプセル・タブレット(サプリメント用)
  • その他

第8章 ドライアイ症候群治療市場:販売チャネル別、推定・動向分析

  • セグメントダッシュボード
  • ドライアイ症候群治療市場:販売チャネル変動分析
  • ドライアイ症候群治療市場:販売チャネル別展望
  • 2018~2030年の市場規模と予測と動向分析
  • 処方
  • 店頭
  • その他

第9章 ドライアイ症候群治療市場:流通チャネル別、推定・動向分析

  • セグメントダッシュボード
  • ドライアイ症候群治療市場:流通チャネル変動分析
  • ドライアイ症候群治療市場:流通チャネル別展望
  • 2018~2030年の市場規模と予測と動向分析
  • 小売薬局
  • 病院薬局
  • オンライン薬局

第10章 ドライアイ症候群治療市場:地域別、推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018~2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第11章 競合情勢

  • 企業分類
  • 主要市場参入企業による最近の動向と影響分析
  • 企業市場シェア分析、2024年
  • 企業概要
    • Novartis AG
    • AbbVie, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Santen Pharmaceutical Co Ltd.
    • AFT Pharmaceuticals
    • Johnson & Johnson Services, Inc.
    • Otsuka Pharmaceutical Co., Ltd.(Otsuka Holdings Co., Ltd.の子会社)
    • OASIS Medical
    • Oyster Point Pharma, Inc.(2023年1月にViatris Inc.に買収)
    • Bausch Health Companies, Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 4 Global dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 5 Global dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 6 Global dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 7 Global dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 8 Global dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 9 North America dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 10 North America dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 11 North America dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 12 North America dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 13 North America dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 14 North America dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 15 North America dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 16 U.S. dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 17 U.S. dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 18 U.S. dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 19 U.S. dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 20 U.S. dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 21 U.S. dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 22 Canada dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 23 Canada dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 24 Canada dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 25 Canada dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 26 Canada dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 27 Canada dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 28 Mexico dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 29 Mexico dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 30 Mexico dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 31 Mexico dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 32 Mexico dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 33 Mexico dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 34 Europe dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 35 Europe dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 36 Europe dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 37 Europe dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 38 Europe dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 39 Europe dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 40 Europe dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 41 UK dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 42 UK dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 43 UK dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 44 UK dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 45 UK dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 46 UK dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 47 Germany dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 48 Germany dry eye syndrome treatment, by drugs 2018 - 2030 (USD Billion)
  • Table 49 Germany dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 50 Germany dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 51 Germany dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 52 Germany dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 53 France dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 54 France dry eye syndrome treatment, by drugs 2018 - 2030 (USD Billion)
  • Table 55 France dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 56 France dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 57 France dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 58 France dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 59 Italy dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 60 Italy dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 61 Italy dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 62 Italy dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 63 Italy dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 64 Italy dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 65 Spain dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 66 Spain dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 67 Spain dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 68 Spain dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 69 Spain dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 70 Spain dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 71 Denmark dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 72 Denmark dry eye syndrome treatment, by drugs 2018 - 2030 (USD Billion)
  • Table 73 Denmark dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 74 Denmark dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 75 Denmark dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 76 Denmark dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 77 Norway dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 78 Norway dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 79 Norway dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 80 Norway dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 81 Norway dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 82 Norway dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 83 Sweden dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 84 Sweden dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 85 Sweden dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 86 Sweden dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 87 Sweden dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 88 Sweden dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 89 Asia Pacific dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 90 Asia Pacific dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 91 Asia Pacific dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 92 Asia Pacific dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 93 Asia Pacific dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 94 Asia Pacific dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 95 Asia Pacific dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 96 Japan dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 97 Japan dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 98 Japan dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 99 Japan dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 100 Japan dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 101 Japan dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 102 China dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 103 China dry eye syndrome treatment, by drugs 2018 - 2030 (USD Billion)
  • Table 104 China dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 105 China dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 106 China dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 107 China dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 108 India dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 109 India dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 110 India dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 111 India dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 112 India dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 113 India dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 114 Australia dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 115 Australia dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 116 Australia dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 117 Australia dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 118 Australia dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 119 Australia dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 120 South Korea dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 121 South Korea dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 122 South Korea dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 123 South Korea dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 124 South Korea dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 125 South Korea dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 126 Thailand dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 127 Thailand dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 128 Thailand dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 129 Thailand dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 130 Thailand dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 131 Thailand dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 132 Latin America dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 133 Latin America dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 134 Latin America dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 135 Latin America dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 136 Latin America dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 137 Latin America dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 138 Latin America dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 139 Latin America dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 140 Brazil dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 141 Brazil dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 142 Brazil dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 143 Brazil dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 144 Brazil dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 145 Brazil dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 146 Brazil dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 147 Argentina dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 148 Argentina dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 149 Argentina dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 150 Argentina dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 151 Argentina dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 152 Argentina dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 153 Argentina dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 154 Middle East & Africa dry eye syndrome treatment, by country, 2018 - 2030 (USD Billion)
  • Table 155 Middle East & Africa dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 156 Middle East & Africa dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 157 Middle East & Africa dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 158 Middle East & Africa dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 159 Middle East & Africa dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 160 Middle East & Africa dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 161 Middle East & Africa dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 162 South Africa dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 163 South Africa dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 164 South Africa dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 165 South Africa dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 166 South Africa dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 167 South Africa dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 168 South Africa dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 169 Saudi Arabia dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 170 Saudi Arabia dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 171 Saudi Arabia dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 172 Saudi Arabia dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 173 Saudi Arabia dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 174 Saudi Arabia dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 175 Saudi Arabia dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 176 UAE dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 177 UAE dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 178 UAE dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 179 UAE dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 180 UAE dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 181 UAE dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 182 UAE dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion
  • Table 183 Kuwait dry eye syndrome treatment, by type, 2018 - 2030 (USD Billion)
  • Table 184 Kuwait dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 185 Kuwait dry eye syndrome treatment, by drugs, 2018 - 2030 (USD Billion)
  • Table 186 Kuwait dry eye syndrome treatment, by product, 2018 - 2030 (USD Billion)
  • Table 187 Kuwait dry eye syndrome treatment, by dosage form, 2018 - 2030 (USD Billion)
  • Table 188 Kuwait dry eye syndrome treatment, by sales channel, 2018 - 2030 (USD Billion)
  • Table 189 Kuwait dry eye syndrome treatment, by distribution channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Dry eye syndrome treatment market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Dry eye syndrome treatment market: Type outlook and key takeaways
  • Fig. 12 Dry eye syndrome treatment market: Type movement analysis
  • Fig. 13 Evaporative dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Aqueous deficient dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Dry eye syndrome treatment market: Drugs outlook and key takeaways
  • Fig. 16 Dry eye syndrome treatment market: Drugs movement analysis
  • Fig. 17 Xiidra dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Restasis dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Cequa dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Tyrvaya dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Eysuvis dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Dry eye syndrome treatment market: Dosage form outlook and key takeaways
  • Fig. 24 Dry eye syndrome treatment market: Dosage form movement analysis
  • Fig. 25 Eye drops/ solutions dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Ointments and gels dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Capsules & tablets (for supplements) dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Other dosage forms dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Dry eye syndrome treatment market: Sales channel outlook and key takeaways
  • Fig. 30 Dry eye syndrome treatment market: Sales channel movement analysis
  • Fig. 31 Prescription dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 OTC dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Dry eye syndrome treatment market: Distribution channel outlook and key takeaways
  • Fig. 35 Dry eye syndrome treatment market: Distribution channel movement analysis
  • Fig. 36 Retail Pharmacies dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Hospital Pharmacies dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Online Pharmacies dry eye syndrome market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Dry Eye Syndrome Treatment Market: Regional outlook and key takeaways
  • Fig. 40 Dry eye syndrome treatment: Regional movement analysis
  • Fig. 41 Dry eye disease syndrome market: regional key takeaways (USD Billion)
  • Fig. 42 Dry eye disease syndrome market: regional outlook, 2024 & 2030, USD Billion
  • Fig. 43 North America dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 U.S. dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Canada dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 Mexico dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Europe dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 UK dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 49 Germany dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 50 France dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 Spain dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Italy dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Norway dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 Denmark dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Sweden dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 Asia Pacific dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 57 China dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 58 Japan dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 59 India dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 60 South Korea dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 61 Australia dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 62 Thailand dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 63 Latin America dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 64 Brazil dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 65 Argentina dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 66 Middle East and Africa dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 67 South Africa dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 68 Saudi Arabia dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 69 UAE dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 70 Kuwait dry eye syndrome treatment market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 List of key emerging company's/technology disruptors/innovators
目次
Product Code: GVR-4-68039-974-4

Dry Eye Syndrome Treatment Market Growth & Trends:

The global dry eye syndrome treatment market size is estimated to reach USD 9.20 billion by 2030, expanding at a CAGR of 6.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as the increasing use of screens, the rising geriatric population, and a heightened prevalence of eye diseases.

The heightened use of devices with a screen, surging use of computers, and a decreased number of blinks are subsequently leading to the growth of evaporative dry eye syndrome globally. For instance, as per Frontiers Journal in 2021, when compared to pre-pandemic years, the use of screens has increased by 60-80% in adults during the COVID-19 pandemic. The exposure to the screen leads to a 66% decreased blinking rate, thus escalating the evaporation of tears and leading to dry eye disease.

Over-the-counter (OTC) products predominate the marketplace due to the extremely low acceptance of prescription products. For instance, only 10% of the diagnosed population is on prescription therapies, while 75% of the population has never tried prescription therapy. However, the number of patients diagnosed with dry eye syndrome accounts for 5-35% of overall ophthalmologist visits.

Moreover, existing products such as Xiidra and Restasis take months or weeks to demonstrate effects. In addition, as per eye consultants, these products have tolerability issues and a failure rate of as high as 50%. This depicts an unmet need in the market and is anticipated to create a lucrative opportunity for pipeline products expected to launch in the upcoming years. Moreover, regulations associated with the drugs further hamper the growth of the overall market. For instance, in 2020, Novartis had to voluntarily withdraw the use of Xiidra in Europe after regulators raised major objections to its use of xiidra.

Innovations and strategic initiatives by key players are driving the market. New product launch is a common strategy being used by the players. For instance, in October 2021, Tyrvaya (varenicline solution) nasal spray by Oyster Point Pharma was approved by the FDA as an alternative treatment approach.

Dry Eye Syndrome Treatment Market Report Highlights:

  • By type, Evaporative dry eye syndrome segment dominated the market with the largest market share in 2024 and is also anticipated to grow with the fastest CAGR during the forecast period
  • Based on dosage form, The eye drops/ solutions segment dominated the market with the largest share of 64.68% in 2024
  • By drug, The Xiidra segment dominated the overall market in 2024, with a revenue share of 8.52%.
  • Based on distribution channel, online pharmacies are expected to grow at the fastest rate over the forecast period due to the increased consumer preference for online pharmacies owing to the convenience
  • North America dominated the market in 2023 due to the high prevalence of the disease, surging awareness, and enhanced treatment rate

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drugs
    • 1.2.3. Product
    • 1.2.4. Dosage Form
    • 1.2.5. Sales Channel
    • 1.2.6. Distribution Channel
    • 1.2.7. Regional Scope
    • 1.2.8. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Drugs outlook
    • 2.2.3. Product outlook
    • 2.2.4. Dosage form outlook
    • 2.2.5. Sales channel outlook
    • 2.2.6. Distribution channel outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Dry Eye Syndrome Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing geriatric population
      • 3.2.1.2. Increasing prevalence of dry eye syndrome
      • 3.2.1.3. Robust product pipeline
      • 3.2.1.4. Growing disease awareness and increasing use of contact lenses
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Competition from generic products
      • 3.2.2.2. High cost of treatments and lack of awareness among the general population in low- and middle-income countries
  • 3.3. Dry Eye Syndrome Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Dry Eye Syndrome Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Dry Eye Syndrome Treatment Market: Type Movement Analysis
  • 4.3. Dry Eye Syndrome Treatment Market by Type Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Evaporative Dry Eye Syndrome
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Aqueous Deficient Dry Eye Syndrome
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Dry Eye Syndrome Treatment Market: Drugs Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Dry Eye Syndrome Treatment Market: Drugs Movement Analysis
  • 5.3. Dry Eye Syndrome Treatment Market by Drugs Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Xiidra
    • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Restasis
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Cequa
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.8. Tyrvaya
    • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.9. Eysuvis
    • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Dry Eye Syndrome Treatment Market: Product Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Dry Eye Syndrome Treatment Market: Product Movement Analysis
  • 6.3. Dry Eye Syndrome Treatment Market by Product Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Artificial Tears
    • 6.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6. Cyclosporine
    • 6.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7. Topical Corticosteroids
    • 6.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8. Punctal Plugs
    • 6.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9. Oral Omega Supplements
    • 6.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.10. Others
    • 6.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7. Dry Eye Syndrome Treatment Market: Dosage Form Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Dry Eye Syndrome Treatment Market: Dosage Form Movement Analysis
  • 7.3. Dry Eye Syndrome Treatment Market by Dosage Form Outlook (USD Million)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Eye Drops/ Solutions
    • 7.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.6. Ointments and Gels
    • 7.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.7. Capsules & Tablets (For Supplements)
    • 7.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.8. Other Dosage Forms
    • 7.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8. Dry Eye Syndrome Treatment Market: Sales Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Dry Eye Syndrome Treatment Market: Sales Channel Movement Analysis
  • 8.3. Dry Eye Syndrome Treatment Market by Sales Channel Outlook (USD Million)
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.5. Prescription
    • 8.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.6. OTC
    • 8.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.7. Others
    • 8.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9. Dry Eye Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Dry Eye Syndrome Treatment Market: Distribution Channel Movement Analysis
  • 9.3. Dry Eye Syndrome Treatment Market by Distribution Channel Outlook (USD Million)
  • 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 9.5. Retail Pharmacies
    • 9.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.6. Hospital Pharmacies
    • 9.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.7. Online Pharmacies
    • 9.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 10. Dry Eye Syndrome Treatment Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Dashboard
  • 10.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.3. North America
    • 10.3.1. U.S.
      • 10.3.1.1. Key country dynamics
      • 10.3.1.2. Regulatory framework/ reimbursement structure
      • 10.3.1.3. Competitive scenario
      • 10.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.2. Canada
      • 10.3.2.1. Key country dynamics
      • 10.3.2.2. Regulatory framework/ reimbursement structure
      • 10.3.2.3. Competitive scenario
      • 10.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.3.3. Mexico
      • 10.3.3.1. Key country dynamics
      • 10.3.3.2. Regulatory framework/ reimbursement structure
      • 10.3.3.3. Competitive scenario
      • 10.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.4. Europe
    • 10.4.1. UK
      • 10.4.1.1. Key country dynamics
      • 10.4.1.2. Regulatory framework/ reimbursement structure
      • 10.4.1.3. Competitive scenario
      • 10.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.2. Germany
      • 10.4.2.1. Key country dynamics
      • 10.4.2.2. Regulatory framework/ reimbursement structure
      • 10.4.2.3. Competitive scenario
      • 10.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.3. France
      • 10.4.3.1. Key country dynamics
      • 10.4.3.2. Regulatory framework/ reimbursement structure
      • 10.4.3.3. Competitive scenario
      • 10.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.4. Italy
      • 10.4.4.1. Key country dynamics
      • 10.4.4.2. Regulatory framework/ reimbursement structure
      • 10.4.4.3. Competitive scenario
      • 10.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.5. Spain
      • 10.4.5.1. Key country dynamics
      • 10.4.5.2. Regulatory framework/ reimbursement structure
      • 10.4.5.3. Competitive scenario
      • 10.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.6. Norway
      • 10.4.6.1. Key country dynamics
      • 10.4.6.2. Regulatory framework/ reimbursement structure
      • 10.4.6.3. Competitive scenario
      • 10.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.7. Sweden
      • 10.4.7.1. Key country dynamics
      • 10.4.7.2. Regulatory framework/ reimbursement structure
      • 10.4.7.3. Competitive scenario
      • 10.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.4.8. Denmark
      • 10.4.8.1. Key country dynamics
      • 10.4.8.2. Regulatory framework/ reimbursement structure
      • 10.4.8.3. Competitive scenario
      • 10.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.5. Asia Pacific
    • 10.5.1. Japan
      • 10.5.1.1. Key country dynamics
      • 10.5.1.2. Regulatory framework/ reimbursement structure
      • 10.5.1.3. Competitive scenario
      • 10.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.2. China
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework/ reimbursement structure
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.3. India
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework/ reimbursement structure
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.4. Australia
      • 10.5.4.1. Key country dynamics
      • 10.5.4.2. Regulatory framework/ reimbursement structure
      • 10.5.4.3. Competitive scenario
      • 10.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.5. South Korea
      • 10.5.5.1. Key country dynamics
      • 10.5.5.2. Regulatory framework/ reimbursement structure
      • 10.5.5.3. Competitive scenario
      • 10.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.6. Thailand
      • 10.5.6.1. Key country dynamics
      • 10.5.6.2. Regulatory framework/ reimbursement structure
      • 10.5.6.3. Competitive scenario
      • 10.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6. Latin America
    • 10.6.1. Brazil
      • 10.6.1.1. Key country dynamics
      • 10.6.1.2. Regulatory framework/ reimbursement structure
      • 10.6.1.3. Competitive scenario
      • 10.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.2. Argentina
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework/ reimbursement structure
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7. MEA
    • 10.7.1. South Africa
      • 10.7.1.1. Key country dynamics
      • 10.7.1.2. Regulatory framework/ reimbursement structure
      • 10.7.1.3. Competitive scenario
      • 10.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.2. Saudi Arabia
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework/ reimbursement structure
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.3. UAE
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework/ reimbursement structure
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.4. Kuwait
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework/ reimbursement structure
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Company Categorization
  • 11.2. Recent Developments & Impact Analysis by Key Market Participants
  • 11.3. Company Market Share Analysis, 2024
  • 11.4. Company overview
    • 11.4.1. Novartis AG
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Financial performance
      • 11.4.1.3. Product benchmarking
      • 11.4.1.4. Strategic initiatives
    • 11.4.2. AbbVie, Inc.
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Financial performance
      • 11.4.2.3. Product benchmarking
      • 11.4.2.4. Strategic initiatives
    • 11.4.3. Sun Pharmaceutical Industries Ltd.
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Financial performance
      • 11.4.3.3. Product benchmarking
      • 11.4.3.4. Strategic initiatives
    • 11.4.4. Santen Pharmaceutical Co Ltd.
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Financial performance
      • 11.4.4.3. Product benchmarking
      • 11.4.4.4. Strategic initiatives
    • 11.4.5. AFT Pharmaceuticals
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Financial performance
      • 11.4.5.3. Product benchmarking
      • 11.4.5.4. Strategic initiatives
    • 11.4.6. Johnson & Johnson Services, Inc.
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Financial performance
      • 11.4.6.3. Product benchmarking
      • 11.4.6.4. Strategic initiatives
    • 11.4.7. Otsuka Pharmaceutical Co., Ltd. (subsidiary of Otsuka Holdings Co., Ltd.)
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Financial performance
      • 11.4.7.3. Product benchmarking
      • 11.4.7.4. Strategic initiatives
    • 11.4.8. OASIS Medical
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Financial performance
      • 11.4.8.3. Product benchmarking
      • 11.4.8.4. Strategic initiatives
    • 11.4.9. Oyster Point Pharma, Inc. (acquired by Viatris Inc. in January 2023)
      • 11.4.9.1. Company Overview
      • 11.4.9.2. Financial performance
      • 11.4.9.3. Product benchmarking
      • 11.4.9.4. Strategic initiatives
    • 11.4.10. Bausch Health Companies, Inc.
      • 11.4.10.1. Company Overview
      • 11.4.10.2. Financial performance
      • 11.4.10.3. Product benchmarking
      • 11.4.10.4. Strategic initiatives